NO322894B1 - Antitrombotisk og antiaterogen farmasoytisk sammensetning inneholdende et thienopyridinderivat og en HMG-CoA-reduktase inhibitor samt anvendelse derav for fremstilling av et antitrombotisk medikament - Google Patents

Antitrombotisk og antiaterogen farmasoytisk sammensetning inneholdende et thienopyridinderivat og en HMG-CoA-reduktase inhibitor samt anvendelse derav for fremstilling av et antitrombotisk medikament Download PDF

Info

Publication number: NO322894B1
Authority: NO; Norway
Prior art keywords: formula; simvastatin; composition according; hmg; coa reductase
Prior art date: 1996-07-26

Application number

NO19990321A

Other languages

English (en)

Norwegian (no)

Other versions

NO990321D0 (no

NO990321L (no

Inventor

Jean-Marc Herbert

Georges Daste

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-26

Filing date

1999-01-25

Publication date

2006-12-18

1999-01-25 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

1999-01-25 Publication of NO990321D0 publication Critical patent/NO990321D0/no

1999-03-22 Publication of NO990321L publication Critical patent/NO990321L/no

2006-12-18 Publication of NO322894B1 publication Critical patent/NO322894B1/no

Links

DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 title claims abstract description 25
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 22
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
239000003146 anticoagulant agent Substances 0.000 title claims description 6
230000000489 anti-atherogenic effect Effects 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title claims description 5
229940127217 antithrombotic drug Drugs 0.000 title claims description 4
230000002785 anti-thrombosis Effects 0.000 title description 5
150000003839 salts Chemical class 0.000 claims abstract description 22
239000001257 hydrogen Substances 0.000 claims abstract description 16
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 11
125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 8
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 37
229960002855 simvastatin Drugs 0.000 claims description 37
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 37
VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 claims description 28
229960001495 pravastatin sodium Drugs 0.000 claims description 28
239000000203 mixture Substances 0.000 claims description 22
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
229950010477 clopidogrel hydrogen sulphate Drugs 0.000 claims description 18
FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical group OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 14
229960002961 ticlopidine hydrochloride Drugs 0.000 claims description 13
MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical group [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 claims description 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
150000002790 naphthalenes Chemical class 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
125000000753 cycloalkyl group Chemical group 0.000 claims description 6
239000012458 free base Substances 0.000 claims description 6
125000004430 oxygen atom Chemical group O* 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
-1 (C2-Ci0)-alkenyl Chemical group 0.000 claims description 2
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229950009116 mevastatin Drugs 0.000 claims description 2
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 2
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
229960005370 atorvastatin Drugs 0.000 claims 1
229960005110 cerivastatin Drugs 0.000 claims 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
229960004844 lovastatin Drugs 0.000 claims 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
239000003826 tablet Substances 0.000 description 12
239000002552 dosage form Substances 0.000 description 8
239000007903 gelatin capsule Substances 0.000 description 8
229940125670 thienopyridine Drugs 0.000 description 8
239000002175 thienopyridine Substances 0.000 description 8
239000005552 B01AC04 - Clopidogrel Substances 0.000 description 7
229960003009 clopidogrel Drugs 0.000 description 7
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 7
239000008187 granular material Substances 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
241001465754 Metazoa Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
210000000329 smooth muscle myocyte Anatomy 0.000 description 5
229920000858 Cyclodextrin Polymers 0.000 description 4
230000003902 lesion Effects 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 4
239000005528 B01AC05 - Ticlopidine Substances 0.000 description 3
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000003038 endothelium Anatomy 0.000 description 3
229960002275 pentobarbital sodium Drugs 0.000 description 3
229960005001 ticlopidine Drugs 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
206010002388 Angina unstable Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000283977 Oryctolagus Species 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
229940127218 antiplatelet drug Drugs 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
125000006725 C1-C10 alkenyl group Chemical group 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000002600 fibrillogenic effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
229940080345 gamma-cyclodextrin Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K41/00—Spindle sealings
- F16K41/02—Spindle sealings with stuffing-box ; Sealing rings
- F16K41/04—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing
- F16K41/043—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles
- F16K41/046—Spindle sealings with stuffing-box ; Sealing rings with at least one ring of rubber or like material between spindle and housing for spindles which only rotate, i.e. non-rising spindles for rotating valves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02D—CONTROLLING COMBUSTION ENGINES
- F02D9/00—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits
- F02D9/04—Controlling engines by throttling air or fuel-and-air induction conduits or exhaust conduits concerning exhaust conduits
- F02D9/06—Exhaust brakes
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K1/00—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces
- F16K1/16—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members
- F16K1/18—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps
- F16K1/22—Lift valves or globe valves, i.e. cut-off apparatus with closure members having at least a component of their opening and closing motion perpendicular to the closing faces with pivoted closure-members with pivoted discs or flaps with axis of rotation crossing the valve member, e.g. butterfly valves

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mechanical Engineering (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Combustion & Propulsion (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19990321A 1996-07-26 1999-01-25 Antitrombotisk og antiaterogen farmasoytisk sammensetning inneholdende et thienopyridinderivat og en HMG-CoA-reduktase inhibitor samt anvendelse derav for fremstilling av et antitrombotisk medikament NO322894B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9609474A FR2751540B1 (fr)	1996-07-26	1996-07-26	Composition pharmaceutique antithrombotique
PCT/FR1997/001353 WO1998004259A1 (fr)	1996-07-26	1997-07-21	COMPOSITION PHARMACEUTIQUE ANTITHROMBOTIQUE ET ANTIATHEROGENE COMPRENANT UN DERIVE DE THIENOPYRIDINE ET UN INHIBITEUR DE LA HMG-CoA-REDUCTASE

Publications (3)

Publication Number	Publication Date
NO990321D0 NO990321D0 (no)	1999-01-25
NO990321L NO990321L (no)	1999-03-22
NO322894B1 true NO322894B1 (no)	2006-12-18

Family

ID=9494551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990321A NO322894B1 (no)	1996-07-26	1999-01-25	Antitrombotisk og antiaterogen farmasoytisk sammensetning inneholdende et thienopyridinderivat og en HMG-CoA-reduktase inhibitor samt anvendelse derav for fremstilling av et antitrombotisk medikament

Country Status (34)

Country	Link
US (1)	US6218403B1 (cs)
EP (1)	EP0914124B1 (cs)
JP (1)	JP3553610B2 (cs)
KR (1)	KR100307268B1 (cs)
CN (1)	CN1109547C (cs)
AR (1)	AR008782A1 (cs)
AT (1)	ATE258052T1 (cs)
AU (1)	AU725949B2 (cs)
BR (1)	BR9710560B1 (cs)
CA (1)	CA2261099C (cs)
CZ (1)	CZ294664B6 (cs)
DE (1)	DE69727299T2 (cs)
DK (1)	DK0914124T3 (cs)
EE (1)	EE03853B1 (cs)
ES (1)	ES2214632T3 (cs)
FR (1)	FR2751540B1 (cs)
HU (1)	HU226245B1 (cs)
ID (1)	ID17774A (cs)
IL (1)	IL128102A0 (cs)
IS (1)	IS2052B (cs)
MY (1)	MY125051A (cs)
NO (1)	NO322894B1 (cs)
NZ (1)	NZ333826A (cs)
PL (1)	PL188739B1 (cs)
PT (1)	PT914124E (cs)
RS (1)	RS49504B (cs)
RU (1)	RU2176504C2 (cs)
SI (1)	SI0914124T1 (cs)
SK (1)	SK284944B6 (cs)
TR (1)	TR199900154T2 (cs)
TW (1)	TW442289B (cs)
UA (1)	UA58518C2 (cs)
WO (1)	WO1998004259A1 (cs)
ZA (1)	ZA976247B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2769313B1 (fr) *	1997-10-06	2000-04-21	Sanofi Sa	Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese
US7141602B2 (en) *	1998-09-18	2006-11-28	Lek Pharmaceuticals D.D.	Process for obtaining HMG-CoA reductase inhibitors of high purity
SI20109A (sl) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
CA2470479A1 (en) *	2001-12-18	2003-06-26	Teva Pharmaceutical Industries Ltd.	Polymorphs of clopidogrel hydrogensulfate
US7074928B2 (en)	2002-01-11	2006-07-11	Teva Pharmaceutical Industries, Ltd.	Polymorphs of clopidogrel hydrogensulfate
AR040588A1 (es) *	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US6800759B2 (en)	2002-08-02	2004-10-05	Teva Pharmaceutical Industries Ltd.	Racemization and enantiomer separation of clopidogrel
IL166593A0 (en)	2002-08-02	2006-01-15		Racemization and enantiomer separation of clopidogrel
DE602004029362D1 (de) *	2003-06-18	2010-11-11	Inst Cardiologie De Montreal M	Vermeidung von vorhofflimmern (af) mit der verwendung von statin
US6978908B2 (en) *	2003-09-15	2005-12-27	Gerber Products Company	Drinking vessel with adjustable handles
RU2261705C1 (ru) *	2004-01-29	2005-10-10	Медведев Илья Николаевич	Способ лечения тромбоцитопатии при метаболическом синдроме
KR100563455B1 (ko) *	2004-04-09	2006-03-23	한미약품 주식회사	결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
SG165379A1 (en) *	2005-09-15	2010-10-28	Otsuka Pharma Co Ltd	Combination drug containing probucol and a tetrazolylalkoxy- dihydrocarbostyril derivative with superoxide supressant effects
US9532945B2 (en) *	2006-04-04	2017-01-03	Kg Acquisition Llc	Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
HUE040311T2 (hu) *	2006-04-04	2019-02-28	Kg Acquisition Llc	Vérlemezke aggregációt gátló szert és sav inhibitort tartalmazó orális dózisformák
EP1931682A2 (en) *	2006-08-03	2008-06-18	Teva Pharmaceutical Industries Ltd.	Process for preparing clopidogrel bisulphate
WO2008060934A2 (en) *	2006-11-14	2008-05-22	Acusphere, Inc.	Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
EP2155168A2 (en) *	2007-04-09	2010-02-24	USV Limited	Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
EP2148655B1 (en) *	2007-04-20	2013-02-27	Wockhardt Limited	Pharmaceutical compositions of clopidogrel
US8343995B2 (en) *	2007-04-27	2013-01-01	Cydex Pharmaceuticals, Inc.	Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP2303233B1 (en) *	2008-07-25	2012-06-20	Pharmathen S.A.	Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
RU2396079C1 (ru) *	2008-12-03	2010-08-10	Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) (статус государственного учреждения)	Лекарственное средство с гиполипидемическим эффектом "аторваглизин"
EA021588B1 (ru)	2009-06-25	2015-07-30	Тетра Сиа	Бетаиновые соли ацетилсалициловой кислоты
JP2020507621A (ja)	2017-01-23	2020-03-12	ドンファファーマシューティカルカンパニーリミテッド	ＨＭＧ−ＣｏＡ還元酵素阻害剤およびクロピドグレルを含む複合製剤
CN118185711A (zh) *	2024-02-28	2024-06-14	湖北兴福电子材料股份有限公司	一种铜钴钨兼容性好的TiN去除组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2003478A1 (en) *	1988-12-12	1990-06-12	Leonard G. Dennick	Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FR2665440B1 (fr) *	1990-07-31	1994-02-04	Lipha	Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
WO1995011898A1 (en) *	1992-05-12	1995-05-04	Nissan Chemical Industries Ltd.	Condensed pyridine type mevalonolactone intermediate and process for its production
WO1995013063A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5945432A (en) *	1995-12-22	1999-08-31	The University Of Vermont And State Agricultural College	Thrombolytic agents and thienopyridine derivatives in acute stroke

1996
- 1996-07-26 FR FR9609474A patent/FR2751540B1/fr not_active Expired - Fee Related
1997
- 1997-07-15 ZA ZA976247A patent/ZA976247B/xx unknown
- 1997-07-15 TW TW086110010A patent/TW442289B/zh not_active IP Right Cessation
- 1997-07-18 AR ARP970103243A patent/AR008782A1/es active IP Right Grant
- 1997-07-21 AU AU38526/97A patent/AU725949B2/en not_active Ceased
- 1997-07-21 HU HU9903752A patent/HU226245B1/hu not_active IP Right Cessation
- 1997-07-21 CZ CZ1999176A patent/CZ294664B6/cs not_active IP Right Cessation
- 1997-07-21 EP EP97935593A patent/EP0914124B1/fr not_active Expired - Lifetime
- 1997-07-21 CN CN97197539A patent/CN1109547C/zh not_active Expired - Fee Related
- 1997-07-21 RU RU99103623/14A patent/RU2176504C2/ru not_active IP Right Cessation
- 1997-07-21 TR TR1999/00154T patent/TR199900154T2/xx unknown
- 1997-07-21 UA UA99021085A patent/UA58518C2/uk unknown
- 1997-07-21 BR BRPI9710560-0B1A patent/BR9710560B1/pt not_active IP Right Cessation
- 1997-07-21 DE DE69727299T patent/DE69727299T2/de not_active Expired - Lifetime
- 1997-07-21 IL IL12810297A patent/IL128102A0/xx not_active IP Right Cessation
- 1997-07-21 PT PT97935593T patent/PT914124E/pt unknown
- 1997-07-21 PL PL97331339A patent/PL188739B1/pl unknown
- 1997-07-21 ES ES97935593T patent/ES2214632T3/es not_active Expired - Lifetime
- 1997-07-21 RS YU3199A patent/RS49504B/sr unknown
- 1997-07-21 EE EEP199900028A patent/EE03853B1/xx not_active IP Right Cessation
- 1997-07-21 SI SI9730622T patent/SI0914124T1/xx unknown
- 1997-07-21 WO PCT/FR1997/001353 patent/WO1998004259A1/fr not_active Ceased
- 1997-07-21 CA CA002261099A patent/CA2261099C/fr not_active Expired - Fee Related
- 1997-07-21 SK SK78-99A patent/SK284944B6/sk not_active IP Right Cessation
- 1997-07-21 AT AT97935593T patent/ATE258052T1/de active
- 1997-07-21 US US09/230,299 patent/US6218403B1/en not_active Expired - Lifetime
- 1997-07-21 NZ NZ333826A patent/NZ333826A/xx not_active IP Right Cessation
- 1997-07-21 JP JP50854598A patent/JP3553610B2/ja not_active Expired - Fee Related
- 1997-07-21 DK DK97935593T patent/DK0914124T3/da active
- 1997-07-24 ID IDP972577A patent/ID17774A/id unknown
- 1997-07-25 MY MYPI97003383A patent/MY125051A/en unknown
1999
- 1999-01-22 IS IS4951A patent/IS2052B/is unknown
- 1999-01-22 KR KR1019997000501A patent/KR100307268B1/ko not_active Expired - Fee Related
- 1999-01-25 NO NO19990321A patent/NO322894B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
RU2176504C2 (ru)	2001-12-10
AU725949B2 (en)	2000-10-26
ATE258052T1 (de)	2004-02-15
CN1109547C (zh)	2003-05-28
NZ333826A (en)	2000-09-29
CA2261099A1 (fr)	1998-02-05
PT914124E (pt)	2004-05-31
PL188739B1 (pl)	2005-04-29
HU226245B1 (en)	2008-07-28
MY125051A (en)	2006-07-31
BR9710560B1 (pt)	2013-12-03
TW442289B (en)	2001-06-23
SI0914124T1 (en)	2004-06-30
SK7899A3 (en)	1999-07-12
PL331339A1 (en)	1999-07-05
IL128102A0 (en)	1999-11-30
IS4951A (is)	1999-01-22
FR2751540A1 (fr)	1998-01-30
CN1228698A (zh)	1999-09-15
NO990321D0 (no)	1999-01-25
KR100307268B1 (ko)	2001-09-24
YU3199A (sh)	2002-09-19
CA2261099C (fr)	2003-04-15
EE03853B1 (et)	2002-10-15
UA58518C2 (uk)	2003-08-15
FR2751540B1 (fr)	1998-10-16
JP3553610B2 (ja)	2004-08-11
HUP9903752A2 (hu)	2000-03-28
SK284944B6 (sk)	2006-03-02
US6218403B1 (en)	2001-04-17
HUP9903752A3 (en)	2001-12-28
EE9900028A (et)	1999-08-16
AU3852697A (en)	1998-02-20
CZ294664B6 (cs)	2005-02-16
ZA976247B (en)	1999-01-15
AR008782A1 (es)	2000-02-23
WO1998004259A1 (fr)	1998-02-05
JP2000500781A (ja)	2000-01-25
CZ17699A3 (cs)	1999-05-12
EP0914124A1 (fr)	1999-05-12
NO990321L (no)	1999-03-22
DE69727299D1 (de)	2004-02-26
TR199900154T2 (xx)	1999-04-21
BR9710560A (pt)	1999-08-17
RS49504B (sr)	2006-10-27
IS2052B (is)	2005-10-14
DE69727299T2 (de)	2004-10-21
ID17774A (id)	1998-01-29
ES2214632T3 (es)	2004-09-16
HK1019405A1 (en)	2000-02-11
EP0914124B1 (fr)	2004-01-21
DK0914124T3 (da)	2004-05-17
KR20000029484A (ko)	2000-05-25

Legal Events

Date	Code	Title	Description
2016-02-29	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6218403B1 (en)	2001-04-17	Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an HMG-CoA-reductase inhibitor
US20100330174A1 (en)	2010-12-30	Betaine compositions
HUT58516A (en)	1992-03-30	Process for producing pharmaceutical compositions comprising pravastatine, suitable for preventing relapse following vasodilator intervention
MXPA03005883A (es)	2005-04-19	Composiciones farmaceuticas que comprenden maleato de amlodipina.
PL193405B1 (pl)	2007-02-28	Zastosowanie wybiórczych inhibitorów pośrednich czynnika Xa w połączeniu z substancją hamującą agregację płytek krwi do wytwarzania leku do leczenia zakrzepowo-zatorowych chorób tętnic oraz preparatyfarmaceutyczne
US4481206A (en)	1984-11-06	Spiro succinimide derivative in the treatment of dementia of the Alzheimer type
KR102139346B1 (ko)	2020-07-29	HMG-CoA 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제
US20110269755A1 (en)	2011-11-03	Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
NO315545B1 (no)	2003-09-22	Blanding med bestemt dose, av en angiotensinkonverterende enzyminhibitor ogav en kalsiumkanal antagonist, fremgangsmåte for fremstilling oganvendelse derav ved behandling av kardiovaskul¶re sykdommer
UA82879C2 (en)	2008-05-26	Method of inhibiting smooth muscle cell contraction
DK169017B1 (da)	1994-08-01	Kombinationspræparat til fælles anvendelse ved behandling af thrombotiske og thromboemboliske sygdomsbilleder indeholdende prostacykliner, analoger heraf eller prostaglandiner (PC/PCA/PG) og thromboxanreceptorantagonister (TXAA), samt anvendelse af PC/PCA/PG og TXAA til fremstilling af et lægemiddel
CA2428204A1 (en)	2002-05-16	Lipid peroxide-lowering compositions
US20050182036A1 (en)	2005-08-18	Medicinal composition containing an HMG-CoA reductase inhibitor
MXPA99000800A (es)	1999-09-20	Composicion farmaceutica antitrombotica
CA2720278A1 (en)	2009-10-08	Agent for preventing and/or treating vascular diseases
HK1019405B (en)	2003-10-17	Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an hmg-coa-reductase inhibitor
US4277481A (en)	1981-07-07	Organic compounds
JP2006176498A (ja)	2006-07-06	血中遊離脂肪酸低下作用を有する医薬組成物
HK1157242A (en)	2012-06-29	Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
AU2002234441A1 (en)	2002-08-19	Glycine betaine and its use as anti-hemorrhagic agent
HK1111356A1 (en)	2008-08-08	Method for reduction, stabilization and prevention of rupture of lipid rich plaque